Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
Conditions
Lung Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Research Site, Beijing, China
Research Site, Beijing, China
Research Site, Changchun, China
Research Site, Changsha, China
Research Site, Chengdu, China
Research Site, Foshan, China
Research Site, Fuzhou, China
Research Site, Guangzhou, China
Research Site, Guangzhou, China
Research Site, Harbin, China
Research Site, Hefei, China
Research Site, Jinan, China
Research Site, Kunming, China
Research Site, Nanchang, China
Research Site, Qingdao, China
Research Site, Shanghai, China
Research Site, Shanghai, China
Research Site, Taiyuan, China
Research Site, Wenzhou, China
Research Site, Xuzhou, China